Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials

• Eastern Cooperative Oncology Group Performance status score of 0 to 2.

• Histologically confirmed CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) and documented in the most recent and representative pathology report, inclusive of the following according to the World Health Organization (WHO) 2022 as per the protocol.

• Must have relapsed or refractory (R/R) disease and have been previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since DLBCL diagnosis.

• Participant must meet at least 1 of the following criteria:

‣ Failed prior autologous stem cell transplant (ASCT), defined as relapsed after ASCT or been refractory to high-dose therapy (HDT)-ASCT.

⁃ Not be considered a candidate for ASCT due to age, performance status, comorbidities and/or insufficient response to prior treatment, or have refused ASCT.

⁃ Be ineligible for or unable to receive chimeric antigen receptor T-cell (CAR-T) meeting at least 1 of the following criteria:

• Unable to receive CAR-T therapy due to fitness and/or comorbidity.

∙ Lymphocyte apheresis failure.

∙ Unwilling to receive CAR-T therapy.

∙ Unable to receive CAR-T therapy due to financial, geographic, insurance, access, and/or manufacturing constraints.

∙ Relapsed/progressed after having achieved at least a Partial Response (PR) or Complete Response (CR) while on prior CAR-T therapy.

• Must have measurable disease.

• Life expectancy \> 3 months on standard of care treatment at the time of enrolling in the study